“These first enrollments reflect more than scientific progress.,” said Thomas Schwaab, M.D., Ph.D., Bank of America Endowed Medical Director of ChristianaCare’s Helen F. Graham Cancer Center & Research Institute.

“They show ChristianaCare’s commitment to giving patients and surrounding communities access to the most advanced cancer treatments available today. By leading early on both studies, the Graham Cancer Center continues to bring innovation, precision and hope directly to the patients we serve.”

These studies are led by NRG Oncology, a National Cancer Institute–funded research group that unites hospitals, scientists and clinical experts nationwide to test and advance the most promising cancer treatments.